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Abstract 
Aims: Estimates of the prevalence of gestational diabetes vary widely. It is important to have a clear 
understanding of the prevalence of this condition to be able to plan interventions and health care 
provision. This paper describes a meta-analysis of primary research data reporting the prevalence of 
gestational diabetes mellitus in the general pregnant population of developed countries in Europe. 
Methods: Four electronic databases were systematically searched in May 2016. English language 
articles reporting gestational diabetes mellitus prevalence using universal screening in general 
pregnant population samples from developed countries in Europe were included.  All papers 
identified by the search were screened by one author, and then half screened independently by a 
second author and half by a third author. Data were extracted by one author. Values for the measures 
of interest were combined using a random effects model and analysis of the effects of moderator 
variables was carried out.  
Results:  A total of 3258 abstracts were screened, with 40 studies included in the review. Overall 
prevalence of gestational diabetes mellitus was 5.4% (3.8-7.8). Maternal age, year of data collection, 
country, area of Europe, week of gestation at testing, and diagnostic criteria were found to have a 
significant univariate effect on GDM prevalence, and area, week of gestation at testing and year of 
data collection remained statistically significant in multivariate analysis. Quality category was 
significant in multivariate but not univariate analysis.  
Conclusions: This meta-analysis shows prevalence of GDM that is at the upper end of previous 
estimates in Europe.  
Keywords: Gestational diabetes mellitus; Prevalence; Europe; Meta-analysis. 
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1. Introduction 
Gestational Diabetes Mellitus (GDM) is defined as glucose intolerance that is first diagnosed in 
pregnancy and increases the risk of complications for both mother and baby during pregnancy [1]. It 
is estimated that GDM affects around 7% of all pregnancies worldwide although prevalence is 
difficult to estimate as rates vary from study to study because of a lack of accepted diagnostic criteria 
and differences in screening procedures [2]. Some earlier diagnostic criteria were based on the criteria 
used in non-pregnant individuals and in others thresholds were created based on the predictive value 
of future type 2 diabetes in the mother.  In recent years, there has been an increasing focus on 
diagnostic thresholds that predict the likelihood of adverse outcomes in pregnancy (HAPO) [3]. 
Adverse outcomes include macrosomia, shoulder dystocia and birth injury, primary caesarean 
delivery, preeclampsia, preterm delivery and foetal and neonatal mortality [4].  
In addition to adverse outcomes during pregnancy and birth, the consequences of GDM extend 
beyond pregnancy with affected women having a seven fold increased risk of type 2 diabetes mellitus 
compared to women who have not had GDM. Rates of type 2 diabetes mellitus after a diagnosis of 
GDM vary depending on the population and length of follow up, but have been reported to be as high 
as 70% [5; 6]. Women are thought to be at the greatest risk of developing type 2 diabetes mellitus in 
the first five years following a pregnancy with GDM, with incidence of type 2 diabetes mellitus 
plateauing at around 10 years [6].  
Although women who have had GDM are at an increased risk of type 2 diabetes mellitus, research has 
shown that by making lifestyle changes they can prevent or delay progression to type 2 diabetes 
mellitus [7]. With prevalence of type 2 diabetes mellitus increasing rapidly, a diagnosis of GDM 
represents an opportunity for intervention to reduce the burden of type 2 diabetes mellitus [8]. This is 
why it is so important to have a full and clear understanding of the prevalence of this condition in 
order to be able to plan such interventions and health care provision. We have therefore conducted a 
meta-analysis of observational primary research studies that have assessed the prevalence of GDM in 
the general population of pregnant women in developed countries in Europe, regardless of the specific 
diagnostic criteria used.  We have derived an overall prevalence estimate for GDM and examined 
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moderator variables that potentially influenced this estimate. Although narrative reviews exist on this 
topic, this is the first systematic review and meta-analysis to bring together and synthesise all the 
evidence.  
2. Material and Methods 
2.1 Literature search and study selection 
A meta-analysis of primary research studies reporting prevalence of GDM was undertaken in 
accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines 
for reviews [9]. A search was conducted in MEDLINE, CINAHL, Health Source and PsycInfo for 
articles published before June 2016. The following combination of search terms were used with each 
database: (prevalence or incidence) and (gestational diabetes or diabetes in pregnancy or gestational 
diabetes mellitus). Reference lists and citations of included papers were checked to identify any other 
potentially relevant papers but key authors and experts in the field were not contacted due to the time 
consuming nature of this process with no guarantee of obtaining relevant information.   
After removing duplicates, the title and abstract of all papers were screened by one author (CE). 
Independent screening of records was split between the two other authors, with JE screening half and 
DC screening the other half. The full texts of papers were retrieved for studies that were considered 
relevant, but also for those that contained insufficient information to allow judgement of relevance. 
These were checked against the inclusion criteria by CE and independently by JE. Reference lists of 
included articles were reviewed to identify any additional relevant articles. In cases of disagreement 
between authors about the inclusion of a paper, the full text of the paper was accessed and consensus 
was reached through discussion.  
Papers were screened against the following inclusion criteria:  
1) Population: general population of pregnant women, living in a developed country in Europe 
(as defined by the Financial Times Stock Exchange). 
 5 
 
2) Outcome measure: prevalence of GDM diagnosed using universal screening carried out in the 
second or third trimester, using either a GTT  alone or two step screening with glucose 
challenge test (GCT) followed by a GTT.  
3)  Study design: observational study, published in English.  
The review was limited to developed countries in Europe because of the wide differences in 
prevalence of type 2 diabetes mellitus and GDM between developed and developing countries [5,10]. 
This removed one potential source of heterogeneity in the review and also ensured its relevance for 
informing care and development of interventions in the context of developed health care systems. 
Studies were defined as having a sample drawn from the general population of pregnant women if it 
was drawn from a source that covered the majority of the population, such as population registers, 
general practice registers or registers of clinics for pregnant women (in countries where registration at 
general practices and clinics for pregnancy women  is near to universal). If this information was not 
reported, studies were only included if the paper explicitly stated that the sample was drawn from a 
general population. Studies that selected people who were at high risk of GDM (due to family history 
of type 2 diabetes mellitus, or lifestyle and medical factors) were excluded. Studies were excluded if 
the majority of the sample were immigrants and did not originate from an included developed 
country. 
2.2 Data extraction and coding 
Data were extracted and summarised from potentially relevant studies by one author (CE) using a 
standardised data extraction form based on the example provided by the Centre for Reviews and 
Dissemination [11]. Confidence intervals were calculated where possible for studies that did not 
report these for prevalence figures. Where there were multiple papers published that were based upon 
the same sample, only the paper reporting the most complete and definitive results was included. 
However, more than one paper from the same sample was included in the review if each paper 
reported on a unique aspect of the findings.   
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The following information was extracted from each included study: first author, journal name and 
year of publication, country of study population, study period, study sample type, study design, age 
range, response rate, sample size, type of screening/testing carried out and diagnostic criteria for 
GDM. The outcome measures extracted were number and proportion of sample with GDM, and 
where reported the number and proportion of sample with GDM by different demographic factors 
such as age and Body Mass Index (BMI).  
Where individual studies reported multiple prevalence estimates according to different diagnostic 
criteria, only one prevalence estimate was included in the meta-analysis to avoid dependency effects. 
The prevalence estimate deriving from the criteria that were most commonly used in other papers in 
the review was the one selected for inclusion in the meta-analysis so that the estimate would be 
comparable to other studies in the review.  For studies reporting multiple prevalence estimates by 
other factors, such as age or year, an average of the estimates was calculated and used in the analysis.    
2.3 Quality appraisal 
 
The quality of included studies was assessed using a checklist based upon the example published by 
the Joanna Briggs Institute [12] which was designed for assessment of quality in systematic reviews 
of prevalence and incidence. Quality assessment was completed for all included papers by one author 
(CE) and a list of all identified weaknesses was compiled.  The list was then discussed by all of the 
authors and the weaknesses were categorised as high, medium or low according to how likely they 
were to put the study at risk of bias. High risk weaknesses were those that put the study at high risk of 
bias or made the risk of bias difficult to assess, and included not reporting participation rate, very low 
participation rate (<50%) or not reporting the source of the study sample (e.g. census, general practice 
register). Participation rates can be defined in many ways but for this review the participation rate 
(recoded during data extraction if necessary and possible) was the proportion of eligible people 
sampled who completed testing for GDM. Medium risk weaknesses included low participation rate 
(50-70%), not reporting women’s gestation at testing and sample size of less than 300. Low risk 
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weaknesses included not reporting characteristics of the sample and not reporting differences between 
participants and non-participants.  
Included studies were then given a quality rating as follows: 
 1: Only low risk weaknesses 
 2: One medium or more than one low risk weakness. 
3:  One high risk or multiple medium risk weaknesses.   
2.4 Data Analysis 
 
The meta-analysis was carried out using the Comprehensive Meta-Analysis software version 3.3.070 
(Biostat, Englewood, NJ). For each study, the proportion of people with GDM was transformed into a 
logit event rate effect size and the standard error associated with this was calculated [13]. The logits 
were retransformed to proportions after analysis to aid interpretation of the results. Combined effect 
sizes were calculated and analyses were carried out twice: both including and excluding outlying logit 
event rates. No significant differences were found between these analyses so outliers were retained in 
the analyses.  
Significance tests and moderator analysis were carried out using a random effects model. Fixed 
effects models make the assumption that the effect size observed in a study estimates the 
corresponding population effect with random error that comes only from the chance factors associated 
with subject level sampling error [13].  In contrast, random effects models allow for the possibility 
that there are also random differences between studies that are not only due to sampling error but as a 
result of some other factor such as variation in procedures, measures or settings. The choice of the 
random effects model to combine studies in this meta-analysis was based upon literature on GDM 
prevalence which suggests that the variability in reported prevalence for GDM may be the result of 
the use of different methodologies and criteria [5].  
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The homogeneity of studies was evaluated using the Q test where the null hypothesis states that 
variability of the effect sizes is the result of sampling error only. If the assumption of homogeneity is 
violated it is customary for sources of variation to be explored by studying moderator variables. Q and 
I
2
 statistics were also calculated to assess differences in combined effect sizes for sets of studies 
grouped according to moderator variables.  
Categorical moderator variables were analysed using an analysis of variance for meta-analysis. 
Differences between subgroups of these variables were explored using a test of interaction. The 
between study homogeneity statistic (QB) reflects the amount of heterogeneity that can be attributed to 
the moderator variable. The within study homogeneity statistic indicates the degree of heterogeneity 
that remains in the category in question (QW) and the I
2 
statistic shows the proportion of the variation 
that is due to heterogeneity rather than sampling error. For continuous variables, a simple weighted 
regression was used, where QR represents the proportion of variability associated with the regression 
model and QE indicates the variability unaccounted for by the model.  
3. Results 
3.1 Description of Included Studies 
Figure 1 shows a PRISMA flow diagram of studies identified by the search. The search identified 
3,258 abstracts of which 161 were potentially relevant after title and abstract screening. The full text 
articles were retrieved and assessed against the inclusion criteria, resulting in 40 included studies 
reported in 41 papers [14-53] (additional papers: [54]). These 40 studies included a total of 1,778,399 
participants. The characteristics of the studies included in the review are presented in Table 1. Studies 
were conducted across 11 of the 17 countries defined as developed European countries: Italy (n=9), 
Sweden (n=7), Spain (n=7), France (n=4), UK (n=5), Ireland (n=2), Belgium (n=2), Greece (n=1), 
Finland (n=1), Austria (n=1), and Switzerland (n=1).   No additional papers were identified by manual 
searching of reference lists.   
Around half of studies (n=22) used a single step screening strategy where all women were given a 
GTT,  and the others used two-step screening, where all women were screened first with a GCT, then 
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those with a positive GCT were given a GTT. Two studies used both one-step screening in one cohort, 
and two-step screening in a second separate cohort of women [28,53]. The most commonly used 
diagnostic criteria were Carpenter and Coustan [55] which were used to diagnose GDM in 14 studies 
as part of two-step screening and one study using one-step screening. The IADPSG criteria [56] were 
applied in a total of ten studies, of which nine used one-step screening and one used two-step 
screening. The NDDG [57] criteria were used in three studies using two-step screening and one study 
using one-step screening. A modification of the EASD criteria [58] that diagnosed GDM on the basis 
of two hour values only without assessing fasting blood glucose was used in four studies all using one 
step screening. Only three studies reported that they tested for and excluded any women with 
undiagnosed pre-existing diabetes that was uncovered in the first trimester.  
3.2 Quality of Studies 
The quality category assigned to each study is reported in Table 1. Three studies were identified that 
had two major weaknesses [59-61]: in all three studies it was not clear if the study sample was a 
whole population of pregnant women and response rates were not reported. These studies were 
excluded from the review as this particular combination of problems made it difficult to assess the 
risk of bias in the study. The majority of included studies were classed as either the higher (n=23) or 
middle quality category (n=11) and therefore had only low or medium risk weaknesses. The 
remaining studies fell in to the lower quality category (n=6) and in addition to any low risk 
weaknesses also had weaknesses that put the study at higher risk of bias. These higher risk 
weaknesses included non-reporting of response rate (n=4), not reporting where women were recruited 
from (n=1) and very low participation rate (n=1). Of the weaknesses categorised as low or medium 
risk, the most common problems were non-reporting of sample characteristics (n=21), non-reporting 
of information on women who did not participate (n=17), low participation rate (n=5), and non-
reporting of gestation at testing (n=2).  
3.3 Analysis of Outliers  
One outlier was identified that reported prevalence of 35.5% [28]. This figure was reported for a 
cohort of women with a median age of 32 and median pre-pregnancy BMI of 22.8kg/m
2 
and who were 
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diagnosed with GDM through universal screening using IADSPG criteria. The majority of women 
were Caucasian (62%) and only 2% had previous GDM. These characteristics are largely similar to 
those of other studies giving no clear explanation for the high prevalence found in this study.   
3.4 Mean Prevalence of GDM 
The mean prevalence of GDM overall was 5.4% (95% CI: 3.8-7.8). The mean prevalence in studies 
using one-step screening was 6.4% (3.8-10.4) and 4.7% (2.7-8.1) in studies using two-step screening. 
There was no significant difference in prevalence of GDM between studies using one-step and two-
step screening (Q[1]=0.64; p=0.424). The analysis of homogeneity in the data with regards to type of 
screening showed variability within studies assessing prevalence using one-step screening 
(Q[19]=13019.04; p<0.001) and those using two-step screening (Q[21]=15517.54; p<0.001). 
3.5 Analysis of Moderators for GDM 
As there was no significant difference in prevalence of GDM by screening type, the analysis of 
prevalence by moderator variables is presented in overall terms. Table 2 shows the individual effects 
of different categorical moderator variables. Sample age, diagnostic criteria, country the study was 
conducted in, year that data collection started and week of gestation at testing, all had a significant 
effect on the prevalence of GDM, whereas the quality category of studies, mean BMI, ethnicity, and 
family history of diabetes in samples, did not have a significant effect. There were too few studies 
reporting parity data for this variable to be included in analyses.  
3.5.1 Sample Age 
Prevalence was higher in samples with a mean age of 30.8 years and over (9.6%; 6.7-13.7) compared 
to those with a mean age of 30.7 and under (4.3%; 2.3-8.0). 
3.5.2 Diagnostic Criteria 
Analysis of the effect of diagnostic criteria on GDM prevalence found the highest prevalence estimate 
in studies using the IADPSG criteria (14.1%; 9-21.5; [56]), the second highest prevalence was found 
in studies using Carpenter and Coustan criteria (6.9%; 5.4-8.7; [55]). The second lowest prevalence 
estimate was in studies using the NDDG criteria (5.3%; 2.7-10; [62]) and the lowest estimate was for 
those that defined GDM using modified EASD criteria with two hour readings only (1.4%; 0.9-2.2).  
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3.5.3 Country 
In the analysis by country, the highest prevalence was found in studies conducted in Italy (10%; 7.6-
13) and the lowest in Sweden (1.5%; 1-2.3). Countries were sorted into three groups according to 
location in Europe: Northern Europe, Western Europe, Southern Europe. Highest prevalence was 
found in countries in Southern Europe (9.6%; 7.3-12.6) and lowest in Northern Europe (2.3%; 1.3-
3.8). 
3.5.4 Year 
Estimates of GDM prevalence increased every decade with the lowest in the 1980s [0.9%; 0.1-10] and 
the highest in the 2010s (11.1%; 5.7-20.6).  
3.5.5 Gestation at testing 
The highest prevalence estimate for GDM was found in studies that screened for GDM at multiple 
time points in the second and third trimester (13.1%; 6.5-24.7) followed by those studies that tested 
participants between 24 and 28 weeks of gestation (7.5%; 5.9-9.4) . The lowest prevalence estimate 
was in a study that screened for GDM at 28 to 32 weeks gestation (1.7%; 1.3-2.2). However, as this 
category only contained a single study this result must be interpreted with caution. The second lowest 
prevalence estimate was found in studies that screened only at 28 weeks of gestation (1.9%; 1.5-2.5). 
3.5.6 Multivariate analysis 
A weighted multiple regression was performed in order to explore which variables made the greatest 
contribution to the variability in prevalence of GDM. All variables explored in the univariate analysis 
were initially entered into the model except for sample age and mean BMI as there were too few 
studies reporting these variables for them to be included in the multivariate analysis. Correlations 
between different variables were explored and used to inform the selection of variables for the 
multiple regression. A moderate correlation was found between year of data collection and diagnostic 
criteria (r=0.478; p=0.010; n=28).The variable diagnostic criteria could not be included in the multiple 
regression because of collinearity with this and other variables.  
The final model included the following variables: quality category, type of screening (one or two 
step), gestation at testing, year data collection started and area of Europe. These variables accounted 
for 83% of total observed variability (QR[11]=125.6, p<0.001, see Table 3 for full results). All three of 
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the variables that were significant in univariate analyses [area, gestation at testing and year of data 
collection] remained statistically significant when the other variables were held constant. Quality 
category and type of screening were not significant in univariate analysis but were significant in the 
multiple regression. However, the residual model was also statistically significant (QE[23]=1134.95; 
p<0.001, I
2
=98.0%) meaning that there was still variability in the data that was not explained by the 
variables analysed. 
4. Discussion 
 
This meta-analysis of 1,770,63  participants in 40 studies reported mean prevalence of GDM of 5.4%. 
No differences were found in prevalence estimates of GDM according to the type of screening used 
(one-step or two-step), mean BMI, ethnicity and family history. An increase in prevalence was found 
with increasing sample age and year of data collection. Diagnostic criteria, country and week of 
gestation at testing were also found to have an effect on GDM prevalence. Nevertheless, given the 
changing migration patterns across Europe, this prevalence estimate may well change in the future. 
The study methods were systematic and robust. We used independent reviewers to screen all of the 
titles and abstracts identified by the search for inclusion in the review. All decisions on the inclusion 
of papers were discussed and agreed upon by all three authors. A thorough quality assessment was 
conducted for all studies considered for inclusion using a template designed for observational 
epidemiology studies and the majority of studies included were of high quality. The methodology had 
only minor limitations: only papers published in the English language were included, experts in the 
field were not contacted, grey literature was not identified and data extraction was only carried out by 
one author.  
The quality assessment ensured that the majority of studies included in the review had relatively good 
participation rates and recruited participants from sources with coverage of the majority of the 
pregnant population (e.g. clinic register) using appropriate methods (e.g. whole population). The 
majority of included studies had good participation rates. Only four studies had participation rates of 
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50 to 70% and only one study had a very low participation rate of less than 50%. This allows us to be 
reasonably confident that the included studies used samples that were representative of the general 
pregnant population. Quality category of the study was not found to have any significant effect on 
prevalence of GDM in univariate analysis but was significant in the multiple regression.  
Non-reporting of various methodological details was a common problem which made it difficult to 
assess fully the quality of some studies.  However, the impact of this problem on the quality of the 
review was minimised by the decision to exclude any studies that had more than one weakness 
defined by the authors as major. Collating data on GDM prevalence was also made difficult by 
heterogeneity in approaches to sampling, methods used to collect blood samples and the criteria used 
to define GDM.  
The way GDM is defined makes it difficult to differentiate between pre-existing undiagnosed diabetes 
and GDM. The IADPSG guidelines suggest that all women or those at high risk have either fasting 
blood glucose, A1c or random blood glucose measured at the first prenatal visit and overt diabetes 
diagnosed if fasting blood glucose is 126mg/dl or higher or A1c 6.5% or higher [56]. Only three of 
the studies included in the present review reported that they tested for pre-existing undiagnosed 
diabetes in this way and excluded any women meeting the criteria. Of these three studies two reported 
the number of women thus identified and in both the prevalence was very low at 0.1% and 0.5%. 
Similarly, analysis of the national health and nutrition examination survey carried out between 1999 
and 2010 in the United States showed that approximately 0.5% of women of non-pregnant women of 
reproductive age had undiagnosed diabetes [63]. Therefore, although estimates of GDM may be 
inflated by the potential inclusion of women with undiagnosed pre-existing diabetes, given the low 
prevalence of this it is unlikely that the effect on GDM estimates would be large.  
The ADA guidelines estimate that around 7% of pregnant women will be diagnosed with GDM [2] 
and a review by of GDM prevalence in Europe reported rates of between 2 and 6% [1]. This estimate 
of 2-6% was based on studies using both risk-based and universal screening, whereas our estimate of 
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5% was based only upon studies using universal screening which identifies more women with GDM 
than risk-based screening [16,42].  
The specific diagnostic criteria was found to have a significant effect on prevalence estimates in this 
review, with the IADPSG [56] criteria giving the highest estimates and a modified EASD [58] and 
Carpenter Coustan [55] giving the lowest estimates. In contrast, the review by Buckley et al. [1;63) 
reported no consistent trend in prevalence according to diagnostic criteria. The IADPSG criteria were 
proposed on the basis of evidence from the HAPO study on the relationship between maternal 
hyperglycaemia and adverse outcomes. A number of associations, including the ADA, have adopted 
these recommendations while others have argued that they will increase prevalence without 
necessarily improving outcomes. A study by Duran et al [26] has since shown that while using the 
IADPSG criteria does increases GDM prevalence, it also result in significant improvements in 
pregnancy outcomes . This study reported increases in prevalence of 3.5 times compared to Carpenter 
and Coustan criteria whereas we found rates according to IADPSG criteria to be around double 
Carpenter and Coustan.   
 The present review confirmed previous research showing that GDM prevalence increases with 
increasing maternal age and is higher in Southern and Western Europe compared to Northern Europe 
[1]. We did not find any effect for BMI, ethnicity or family history, but there were few studies that 
measured or reported these variables so there may have been insufficient power to detect any 
differences.  A strength of the present study is that pooling studies using meta-analysis allows trends 
to be identified when there are inconsistencies between individual studies.  
With GDM being closely linked to type 2 diabetes mellitus and sharing some risk factors, we would 
expect to see an increase in GDM over time [1]. Although we found significant increases in GDM 
prevalence over time, year of data collection was moderately correlated with diagnostic criteria. The 
IADPSG criteria were associated with the highest prevalence estimates for GDM but were also the 
criteria published most recently. It was not possible to enter diagnostic criteria in to the multivariate 
analysis which makes it difficult to assess how much of the increase in prevalence over time was 
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related to the widening of diagnostic criteria and how much it reflected true increases in prevalence. 
Increases in screening over time also makes interpreting trend in prevalence difficult [64], although by 
including only studies using universal screening this source of heterogeneity was removed from this 
review.  
In summary, this is the first meta-analysis to bring together all the relevant evidence relating to GDM 
prevalence in Europe and to make sense of disparate findings. In the general population of developed 
Europe, around 1 in 20 pregnant women meet the criteria for GDM. These figures provide a basis for 
the planning of interventions and health care provision for the prevention of type 2 diabetes mellitus. 
We now recommend that similar meta-analyses be conducted in other populations for comparison, for 
example those from developing countries, and from North America and Asia.  
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Figure 1 – Flow diagram showing study selection 
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Table 1 – Characteristics of studies included in the review. [Large table included in separate file for publication as supplementary information online] 
First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
Åberg, 
Sweden, 
1995-1999 
Prospective 
study of all 
singleton 
pregnant 
women in 
one 
geographic
al area 
12,382 NR NR NR NR One step: 
75g 
OGTT  
27-28 GDM if 2 hour 
value of 9mmol/l or 
more 
1.2% [1.0-
1.4] 
2 
Alberico, 
Italy, 1997-
2000 
Prospective 
study of all 
pregnant 
women at 
one clinic 
856 32.5 NR 61%  NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
6.6% [4.9-
8.2] 
3 
Anderberg, 
Sweden, 
1991-2003 
Retrospecti
ve of all 
pregnant 
women in 
one 
geographic
al area 
129,143 NR NR NR NR One step: 
75g 
OGTT 
28 GDM if 2 hour 
value of 9mmol/l or 
more 
1.2 [1.2-
1.3] 
1 
Avalos, 
Ireland, 
2007-2009 
Retrospecti
ve study of 
all pregnant 
women at 
five clinics 
5,500 32 [5.3] 26.9 
[5.1] 
NR 32% in 
1
st
 or 2
nd
 
degree  
One step: 
75g 
OGTT 
24-28 OGTT interpreted 
according to 
IADPSG and WHO 
2006 
IADPSG: 
12.4% 
[11.5-13.3] 
WHO 
2006: 9.4% 
3 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
[8.7-10.2] 
Breschi, 
Italy, 1988-
1991 
Prospective 
study of all 
pregnant 
women at 
one clinic 
539 29.4 
[4.6] 
22.5 
[3.3] 
Mean: 1.7 34.2%  One step: 
100g 
OGTT 
Mean = 
26 
OGTT interpreted 
according to 
NDDG 
3.2% [1.7-
4.6] 
3 
Bugallo, 
Spain, 2004-
2006 
Retrospecti
ve study of 
all pregnant 
women at 
one 
hospital 
11,628 30 [6] NR NR NR Two step: 
those with 
positive 
50g GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
6.4% [5.9-
6.9] 
1 
Cauza, 
Austria, 
1999-2001 
Prospective 
study of all 
pregnant 
women at 
one 
hospital 
2,421 NR NR NR NR One step: 
75g 
OGTT 
24-28 GDM if 1 hour 
value of 8.9mmol/l 
or more 
8.6% [7.5-
9.7] 
3 
Chevalier, 
France, 
2002-2006 
Prospective 
study of all 
pregnant 
women at 
one 
hospital 
11,545 NR NR 46%  NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.2mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
4.3% [3.9-
4.6] 
1 
Chico, 
Spain, 1999-
2001 
Retrospecti
ve study of 
all pregnant 
6,428 NR NR NR NR Two step: 
those with 
positive 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
NDDG: 
6.5% [5.9-
7.1] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
women at a 
set of 
clinics 
GCT 
given 
100g 
OGTT 
basis of OGTT 
according to 
NDDG Carpenter 
and Coustan 
Carpenter 
and 
Coustan:  
6.8% [6.1-
7.4] 
Coolen, 
Belgium, 
2008 
Prospective 
study of all 
pregnant 
women 
attending 
one clinic 
317 30.6[0.3
] 
NR 33.9%  NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28  GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
3.2% [1.2-
5.1] 
1 
Cordero, 
Spain, NR 
Randomise
d controlled 
trial of 
pregnant 
women in 
one area.  
156 32.9 
[4.5] 
23.6 [4] 47.4%  14.1% 
1
st
 
degree 
and 32% 
2
nd
 
degree.  
Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
NDDG 
8.3% [4-
12.7] 
2 
Corrado, 
Italy, 1990 
Retrospecti
ve study of 
all 
singleton 
pregnant 
women 
seen by 6 
obstetrician
s 
738 NR NR NR NR One step: 
75g 
OGTT 
24-28 OGTT interpreted 
according to 
IADPSG 
11.9% [9.6-
14.3] 
1 
Cosson, Prospective 2,111 29.2 23.4 Mean 12.8% One step: 24-28 OGTT interpreted 12.6% 1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
France, 2002 study of all 
singleton 
pregnant 
women at 
one 
hospital 
[5.8] [4.7] 2.08 [SD 
1.37] 
75g 
OGTT 
according if fasting 
value 5.3mmol/l or 
more [French 
recommendations] 
and/or 2 hour value 
of 7.8 mmol/l or 
more [according to 
WHO 1999]. 
[11.1-14.0] 
Di Cianni, 
Italy, 1995-
2001 
Retrospecti
ve study of 
all pregnant 
women at 
one clinic. 
3,950 31.1 
[4.7] 
22.5 
[3.7] 
56.1%  17.1% Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
8.4% [7.6-
9.3] 
1 
Duran, 
Spain, 2011-
2012 cohort 
1 
Prospective 
study of all 
pregnant 
women at 
one 
hospital 
1,750 32 Median 
22.7 
43.9% 8.4% Two step: 
those with 
positive 
50g GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
10.6% [9.1-
12.0] 
1 
Duran, 
Spain, 2012-
2013 cohort 
2 
All 
pregnant 
women at 
one 
hospital 
1,526 32 Median 
22.8 
44.7%  9.4% One step: 
75g 
OGTT  
24-28 GDM diagnosed 
according to 
IADPSG 
35.5% 
[33.1-37.9] 
1 
Fadl, 
Sweden, 
Retrospecti
ve study of 
1,260,29
7 
NR NR 42% NR Two step: 
those with 
NR RBG of 8mmol/l or 
higher considered 
0.84% 
[0.82-0.86] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
1991-2003 all 
singleton 
pregnant 
women in 
Sweden  
positive 
RBG 
given 75g 
OGTT 
positive. GDM 
diagnosed on basis 
of 75g OGTT if 
fasting value 
6.1mmol/l and/or 2 
hour value of 
9mmol/l or more.  
  
 
Fedele, Italy, 
1990-1991 
Prospective 
study of all 
women 
attending 
family 
planning 
clinics in 
one area 
490 NR NR NR NR Two step: 
those with 
positive 
50g GCT 
given 
100g 
OGTT 
High risk 
women 
10-14, 24-
28 and 
30-32. 
Others 
24-28. 
GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
10.8% [8.1-
13.6] 
1 
Griffin, 
Ireland, NR 
All women 
attending 
one 
hospital 
randomised 
to selective 
or universal 
screening 
1299 27.4 
[5.6] 
During 
pregnan
cy 28.2 
[4] 
39.3% NR Two step: 
those with 
positive 
50g GCT 
given 
100g 
OGTT 
26-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
2.7% [1.8-
3.6] 
2 
Ignell, 
Sweden, 
2014 
Retrospecti
ve study of 
all 
singleton 
156,144 NR NR NR NR One step: 
75g 
OGTT 
28 GDM if 2 hour 
value of 9mmol/l or 
more 
2.2% [2.1-
2.3] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
pregnant 
women in 
two areas.  
Janghornban
i, UK, 1996-
1997 
Prospective 
study of all 
pregnant 
women 
screened in 
one area.  
3,933 NR NR NR NR Two step: 
those with 
positive 
RBG 
given 75g 
OGTT 
24-28 RBG of 6.5mmol/l 
or more positive. 
GDM diagnosed 
according to OGTT 
if 2 hour reading of 
11mmol/l or more 
1.7% [1.3-
2.1] 
1 
Jiménez-
Moleón, 
Spain, 1995 
 
Retrospecti
ve study of 
all 
singleton 
pregnant 
women in 
one 
hospital. 
1,962 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
NDDG 
3.3% [2.5-
4.1] 
1 
Kayema-
Kay, UK, 
1996-1997 
Prospective 
study of all 
singleton 
women at 
one 
hospital 
1484 NR NR NR NR One step: 
75g 
OGTT 
24-28 GDM if 2 hour 
value of 9.0 mmol/l 
or more 
1.2% [0.7-
1.8 
 
Lacaria, 
Italy, 2012-
2013 
Prospective 
study of all 
pregnant 
women in 
two areas. 
2497 33.5 [5] 22.8 [4] NR NR One step: 
75g 
OGTT 
24-28 OGTT interpreted 
according to 
IADPSG 
10.9% 1 
Lind, UK, Prospective 2,285 NR NR NR NR Two step: 28-32 RBG greater than 0.3% [0.1- 1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
1984 study of all 
singleton 
pregnant 
women in 
one clinic. 
those with 
positive 
RBG 
given 75g 
OGTT 
4.3mmol/l to 
6.4mmol/l 
[depending on time 
since meal] 
considered positive. 
GDM diagnosed on 
the basis of OGTT 
2 hour value of 
8.0mmol/l and 
above.  
0.5] 
Lindqvist, 
Sweden, 
2011-2012 
Population 
study of all 
pregnant 
women in 
areas where 
universal 
screening 
offered 
20,822 30 25 NR NR One step: 
75g 
OGTT 
NR GDM if 2 hour 
value  over  
10mmol/l 
2.2% [2-
2.4] 
1 
Malmqvist, 
Sweden, 
1999-2005 
Retrospecti
ve study of 
all 
singleton 
pregnant 
women in 
one area 
81,110 30.4 [5] NR 47.3%  NR One step: 
75g 
OGTT 
28 GDM if 2 hour 
value  over  
10mmol/l 
2% [1.9-
2.1] 
1 
Meek, UK, 
2004-2008 
Retrospecti
ve study of 
all 
singleton 
25,543 30.7[95
% CI 
30.6-
30.8] 
24.8 
[95% CI 
24.6-
24.8] 
38.7%  NR Two step: 
those with 
positive 
GCT 
26-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of 75g OGTT 
4.9% [4.6-
5.2] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
pregnant 
women  in 
one area 
given 75g 
OGTT 
interpreted 
according to 
IADPSG 
Miailhe, 
France, 
2011-2012 
Prospective 
study of all 
singleton 
pregnant 
women in 
one area 
2,187 NR 36% 
with 
BMI 
>25 
41.7%  NR One step: 
75g 
OGTT 
24-28 GDM diagnosed 
according to 
IADPSG 
14% [12.7-
15.6] 
1 
Murgia, 
Italy,  NR 
Prospective 
study of 
pregnant 
women at 
one clinic 
1,103 31 [5] 22.5 
[3.8] 
NR 14.2% 
1
st
 
degree 
Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
16-18, 24-
26 and 
30-32 
GCT of 7.2 mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
16-18: 
6.6% [5.2-
8.1 
24-26: 
5.8% [4.4-
7.2] 
30-32: 
9.9% [8.1-
11.6] 
Total: 22.4 
[19.9-24.9] 
1 
Orecchio, 
Switzerland, 
2004-2005 
Prospective 
study of all 
singleton 
pregnant 
women at 
one 
hospital 
1,042 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT 
24-28 GCT of 7.8 mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
4.8% [3.5-
6.1] 
1 
Oriot, Retrospecti 1,424 NR NR NR NR Two step: 24-28 GCT of 7.8mmol/l 8.2% [6.8- 2 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
Belgium, 
2009-2011, 
cohort 1 
ve study of 
all pregnant 
women at 
one 
hospital 
those with 
positive 
GCT 
given 
100g 
OGTT. 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
9.6] 
Oriot, 
Belgium, 
2011-2012, 
cohort 2 
Retrospecti
ve study of 
all pregnant 
women at 
one 
hospital 
1,206 NR NR NR NR One step: 
75g 
OGTT 
24-28 GDM diagnosed 
according to 
IADPSG 
22.9% 
[20.5-25.3] 
2 
Östlund, 
Sweden,  
1994-1996 
 
Prospective 
study of all 
pregnant 
women in 
one area 
3,616 27.9 
[4.8] 
23.8 
[4.1] 
46%  9.4% One step: 
75g 
OGTT 
28-32 
  
GDM diagnosed 
according to 
IADPSG 
1.7% [1.3-
2.1] 
1 
Pérez-Ferre, 
Spain, 2007-
2008 
 
Retrospecti
ve study of 
all pregnant 
women in 
one area 
1,311 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT. 
Carbohyd
rate rich 
diet 
followed 
24-28 GCT of 7.8mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
5.4% [4.5-
7] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
3 days 
prior to 
OGTT. 
Pintaudi, 
Italy, 2010-
2011 
Retrospecti
ve study of 
all pregnant 
women at 
one clinic 
1,015 NR NR NR NR One step: 
75g 
OGTT 
24-28 GDM diagnosed 
according to 
IADPSG 
11.1% 1 
Pöyhönen-
Alho, 
Finland, 
1996-1998 
 
Prospective 
study of 
pregnant 
women 
from one 
area 
532 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT. 
28 GCT of 7.3mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT with 
fasting values of 
4.8mmol/l or more, 
10mmol/l or more  
at 1 hour or 
8.7mmol/l or more 
at 2 hour. 
2.8% [1.4-
4.2] 
3 
Ricart, 
Spain, 2002 
Prospective 
study of all 
singleton 
pregnant 
women 
from 16 
hospitals 
9,270 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT. 
24-28 GCT of 7.8 mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
NDDG 
8.8% [8.3-
9.4] 
1 
Rüetschi, 
Italy, 2010-
2012 
Retrospecti
ve study of 
all pregnant 
women in 
2,298 31 NR NR NR One step: 
75g 
OGTT 
24-28 GDM diagnosed 
according to 
IADPSG 
10.9% [9.7-
12.3] 
1 
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First author, 
country, 
years data 
collected  
 
Sampling 
Method add 
if singleton 
or twin 
Sample 
Size  
Mean 
Age 
[SD] 
Mean 
BMI 
[SD] 
Parity [% 
nulli-
parous] 
Family 
History 
Screening 
Type 
Gestation 
at testing 
[weeks] 
Criteria Used 
[category] 
Overall 
prevalence 
[95% CI] 
 
Quality 
Score  
 with OGTT 
data in 
laboratories 
in two 
areas 
Sacks, UK, 
2000-2006,  
Prospective 
study of all 
pregnant 
women at 
two study 
centres 
1671 NR NR NR NR One step: 
75g 
OGTT 
24-32 GDM diagnosed 
according to 
IADPSG 
21.3% 
[20.1-22.6] 
3 
Vassilaki, 
Greece, 
2007 
Prospective 
study of 
singleton 
pregnant 
women 
from four 
clinics in 
one area 
1,122 NR NR NR NR One step: 
75g 
OGTT 
24-28 GDM diagnosed 
according to 
Carpenter and 
Coustan 
9.1% [7.4-
10.8] 
2 
Vignoles, 
France, 
2006-2007 
Retrospecti
ve study of 
all 
singleton 
pregnant 
women at 
one 
hospital 
3,237 NR NR NR NR Two step: 
those with 
positive 
GCT 
given 
100g 
OGTT. 
34-32 GCT of 7.2 mmol/l 
or more positive. 
GDM diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
5.1% [4.4-
5.9] 
1 
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Table 2 Mean prevalence of GDM by several moderator variables  
Variable k n Prevalence 95% 
CI 
QB [df] QW [df] I
2 
[%] 
Mean age [years]      
 
  
30.7 and below 9 122,648 4.3% 2.3-
8.0 
4.75 [1]* 
 
2312.38 [8]* 99.7 
30.8 and above 9 43,327 9.6% 6.7-
13.7 
806.49 [8]* 99 
Diagnostic Criteria  
 
       
NDDG 4 11,927 5.3% 2.7-
10 
60.1[3]* 79.13 [3]* 96.2 
Carpenter Coustan 15 47,502 6.9% 5.4-
8.7 
 621.28 [14]* 97.7 
EASD 2 hour only 4 299,153 1.4% 0.9-
2.2 
 420.48 [3]* 99.3 
IADPSG 10 46,557 14.1% 8.9-
21.5 
 2275.49[9]* 99.6 
Quality Category        
1 – Higher 24 325,888 6.0% 4.1-
8.5 
3.0 [2] 7999.56 [21]* 99.7 
2 12 1,442,4833 3.9% 2.2-
7.1 
 6869.37 [11]* 99.8 
3 – Lower 6 13,895 7.6% 4.8-
12.0 
 366.60 [5]* 98.6 
Country        
Austria 1 2,421 8.6% 7.5-
9.8 
101.96 
[10]* 
0.00 [0] 0.0 
Belgium 3 2,497 9% 3.3-
22.2 
 133.24 [2]* 98.5 
Finland 1 532 2.8% 1.7-
4.6 
 0.00 [0] 0.0 
France 4 19,080 8% 4.1-
14.9 
 403.18 [3]* 99.26 
Greece 1 1,122 9.1% 7.5-
10.9 
 0.00 [0]  0.0 
Ireland 2 6,799 5.9% 1.3-
23.8 
 85.59 [1] * 9.8 
Italy 9 13,486 10% 7.6-
13 
 210.45 [8]* 96.2 
Spain 8 34,031 8.6% 5.1-
14.1 
 1259.12 [7]* 99.4 
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Sweden 7 1,663,514 1.5% 1-2.3  3335.68 [6]* 99.8 
Switzerland 1 1042 4.8% 3.7-
6.3 
 0.00 [0]  0.0 
UK 5 37,292 2.4% 0.8-
7.0 
 1519.62 [4] * 99.7 
Area of Europe        
Northern 15 1,708,137 2.3% 1.3-
3.8 
24.32 [2] 
* 
14880.94[14]* 99.9 
Western 9 26,346 7.3% 4.6-
11.3 
 651.79 [8]* 98.8 
Southern 18 47,783 9.6% 7.3-
12.6 
 1530.48 [17] * 98.9 
Year data collection 
started 
       
1980-1989 2 2,824 0.9% 0.1-
10 
14.95 [3] 
* 
27.77 [1] * 96.4 
1990-1999 14 1,508,604 2.9% 1.9-
4.5 
 5500.94 [13] * 99.8 
2000-2009 13 233,199 6.9% 4.3-
10.8 
 5434.77 [12] * 99.8 
2010-2016 9 34,343 11.1% 5.7-
20.6 
 2187.66 [8] * 99.6 
% sample with 
family history of 
diabetes 
       
14% and below 5 10,106 12% 5.2-
25.3 
0.971 [1] 804.53 [4] * 99.5 
15% and over 3 9,989 7.6% 4.9-
11.5 
 65.3 [2] * 96.9 
% sample Caucasian         
79% and below 2 3,276 20.3% 5.4-
53.6 
2.73 [1] 265.93 [1] * 99.6 
80% and over 7 102,821 5.5% 2.4-
12.3 
 3040.83 [6] * 99.8 
Gestation at testing        
24-28 weeks 28 105,096 7.5% 5.9-
9.4 
104.85 
[3] * 
2841.69 [27] * 99.1 
28 weeks 6 381,273 1.9% 1.5-
2.5 
 449.79 [5] * 98.9 
28-32 weeks 1 3,616 1.7% 1.3-
2.2 
 0.00 [0] 0.0 
Multiple time points 4 8,877 13.1% 6.5-
24.7 
 367.84 [3] * 99.2 
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Mean BMI        
20-24.9 10 19,131 9.8% 5.5-
16.9 
0.39 [1] 1062.55 [7] * 99.3 
25-29.9 2 6,799 5.9% 1.3-
23.8 
 85.59 [1] * 98.8 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity statistic; QW: 
within study homogeneity statistic; I
2 
proportion of variability within categories due to heterogeneity 
rather than sampling error.  
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Table 3 Weighted multiple regression for GDM prevalence 
  95% CI Q[B] [df] 
Quality Category    
1 – Higher - - 14.85 [2] * 
2 0.042 -0.35-0.44  
3 – Lower 0.97* 0.47-1.47  
Area of Europe    
North  - - 18.07 [2] * 
West 0.54* 0.02-1.06  
South 1.04* 0.54-1.53  
Year data collection started    
1980-1989 - - 29.03 [3] * 
1990-1999 1.85* 0.71-3.0  
2000-2009 2.37* 1.21-3.52  
2010-2016 2.74* 1.61-3.88  
Gestation at testing    
24-28 weeks 0.49 -0.54-1.52 9.58 [3]* 
28 weeks -0.15 -1.11-0.83  
28-32 weeks - -  
Multiple time points 1.03 -0.11-2.17  
Type of Screening    
One step - -  
Two step -0.41* -0.77—0.04  
* p<0.05; QB: between study homogeneity statistic;  
